Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 120

1.

Emerging Targets for the Treatment of Lupus Erythematosus: There is No Royal Road to Treating Lupus.

Yasuda S.

Mod Rheumatol. 2018 Jun 27:1-26. doi: 10.1080/14397595.2018.1493909. [Epub ahead of print]

PMID:
29947283
2.

Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.

Banham GD, Flint SM, Torpey N, Lyons PA, Shanahan DN, Gibson A, Watson CJE, O'Sullivan AM, Chadwick JA, Foster KE, Jones RB, Devey LR, Richards A, Erwig LP, Savage CO, Smith KGC, Henderson RB, Clatworthy MR.

Lancet. 2018 Jun 14. pii: S0140-6736(18)30984-X. doi: 10.1016/S0140-6736(18)30984-X. [Epub ahead of print]

PMID:
29910042
3.

A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.

Doria A, Bass D, Schwarting A, Hammer A, Gordon D, Scheinberg M, Fox NL, Groark J, Stohl W, Kleoudis C, Roth D.

Lupus. 2018 Jan 1:961203318777634. doi: 10.1177/0961203318777634. [Epub ahead of print]

PMID:
29807477
4.

Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year.

Vinod SS, Reed AB, Maxwell J, Cron RQ, Stoll ML.

Pediatr Rheumatol Online J. 2018 Mar 9;16(1):16. doi: 10.1186/s12969-018-0234-0.

5.

Biologics in Inflammatory Immune-mediated Systemic Diseases.

Moroncini G, Calogera G, Benfaremo D, Gabrielli A.

Curr Pharm Biotechnol. 2017;18(12):1008-1016. doi: 10.2174/1389201019666171226152448. Review.

PMID:
29278213
6.

Certolizumab, an anti-TNF safe during pregancy? The CRIB Study results: an interview with Professor Xavier Mariette.

Mariette X.

Immunotherapy. 2017 Sep;9(10):793-795. doi: 10.2217/imt-2017-0099.

PMID:
28877634
7.

Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial.

Emamikia S, Gentline C, Chatzidionysiou K, Arnaud L, van Vollenhoven R.

Scand J Rheumatol. 2018 Mar;47(2):131-140. doi: 10.1080/03009742.2017.1336570. Epub 2017 Sep 1.

PMID:
28862513
8.
9.

A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus.

Chatham W, Chadha A, Fettiplace J, Kleoudis C, Bass D, Roth D, Gordon D.

Lupus. 2017 Dec;26(14):1483-1490. doi: 10.1177/0961203317703495. Epub 2017 May 3.

10.

Belimumab in the management of systemic lupus erythematosus - an update.

Tesar V, Hruskova Z.

Expert Opin Biol Ther. 2017 Jul;17(7):901-908. doi: 10.1080/14712598.2017.1324846. Epub 2017 May 16. Review.

PMID:
28460578
11.

The use of biologics in pregnant patients with rheumatic disease.

Østensen M.

Expert Rev Clin Pharmacol. 2017 Jun;10(6):661-669. doi: 10.1080/17512433.2017.1305268. Epub 2017 Mar 22. Review.

PMID:
28326845
12.

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.

Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, Chow A, Iczkovitz S.

Rheumatol Int. 2017 Jun;37(6):865-873. doi: 10.1007/s00296-017-3682-9. Epub 2017 Mar 9.

13.

Treatment Satisfaction in Systemic Lupus Erythematosus: Development of a Patient-Reported Outcome Measure.

Mathias SD, Berry P, Pascoe K, de Vries J, Askanase AD, Colwell HH, Chang DJ.

J Clin Rheumatol. 2017 Mar;23(2):94-101. doi: 10.1097/RHU.0000000000000495.

14.

Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.

Parodis I, Sjöwall C, Jönsen A, Ramsköld D, Zickert A, Frodlund M, Sohrabian A, Arnaud L, Rönnelid J, Malmström V, Bengtsson AA, Gunnarsson I.

Autoimmun Rev. 2017 Apr;16(4):343-351. doi: 10.1016/j.autrev.2017.02.005. Epub 2017 Feb 13. Review.

PMID:
28216072
15.

Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned.

Forbess LJ, Bresee C, Wallace DJ, Weisman MH.

Lupus. 2017 Aug;26(9):909-916. doi: 10.1177/0961203317692433. Epub 2017 Feb 7.

PMID:
28173737
16.

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.

Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D.

Arthritis Rheumatol. 2017 May;69(5):1016-1027. doi: 10.1002/art.40049. Epub 2017 Apr 7.

17.

It hasn't gone away: the problem of glucocorticoid use in lupus remains.

Apostolopoulos D, Morand EF.

Rheumatology (Oxford). 2017 Apr 1;56(suppl_1):i114-i122. doi: 10.1093/rheumatology/kew406. Review.

PMID:
28013208
18.

Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.

Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B.

Lupus. 2016 Dec;25(14):1587-1596. Epub 2016 Aug 3.

19.

New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.

Staveri C, Karokis D, Liossis SC.

Semin Arthritis Rheum. 2017 Jun;46(6):788-790. doi: 10.1016/j.semarthrit.2016.09.006. Epub 2016 Sep 28.

PMID:
27793432
20.

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
.

Sheikh SZ, Hammer AE, Fox NL, Groark J, Struemper H, Roth D, Gordon D.

Int J Clin Pharmacol Ther. 2016 Nov;54(11):914-922.

Supplemental Content

Loading ...
Support Center